Cargando…
Mesoporous Nanoparticles for Diagnosis and Treatment of Liver Cancer in the Era of Precise Medicine
Primary liver cancer is the seventh-most-common cancer worldwide and the fourth-leading cause of cancer mortality. In the current era of precision medicine, the diagnosis and management of liver cancer are full of challenges and prospects. Mesoporous nanoparticles are often designed as specific carr...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500788/ https://www.ncbi.nlm.nih.gov/pubmed/36145508 http://dx.doi.org/10.3390/pharmaceutics14091760 |
_version_ | 1784795308570443776 |
---|---|
author | Wu, Han Wang, Ming-Da Zhu, Jia-Qi Li, Zhen-Li Wang, Wan-Yin Gu, Li-Hui Shen, Feng Yang, Tian |
author_facet | Wu, Han Wang, Ming-Da Zhu, Jia-Qi Li, Zhen-Li Wang, Wan-Yin Gu, Li-Hui Shen, Feng Yang, Tian |
author_sort | Wu, Han |
collection | PubMed |
description | Primary liver cancer is the seventh-most-common cancer worldwide and the fourth-leading cause of cancer mortality. In the current era of precision medicine, the diagnosis and management of liver cancer are full of challenges and prospects. Mesoporous nanoparticles are often designed as specific carriers of drugs and imaging agents because of their special morphology and physical and chemical properties. In recent years, the design of the elemental composition and morphology of mesoporous nanoparticles have greatly improved their drug-loading efficiency, biocompatibility and biodegradability. Especially in the field of primary liver cancer, mesoporous nanoparticles have been modified as highly tumor-specific imaging contrast agents and targeting therapeutic medicine. Various generations of complexes and structures have been determined for the complicated clinical management requirements. In this review, we summarize these advanced mesoporous designs in the different diagnostic and therapeutic fields of liver cancer and discuss the relevant advantages and disadvantages of transforming applications. By comparing the material properties, drug-delivery characteristics and application methods of different kinds of mesoporous materials in liver cancer, we try to help determine the most suitable drug carriers and information media for future clinical trials. We hope to improve the fabrication of biomedical mesoporous nanoparticles and provide direct evidence for specific cancer management. |
format | Online Article Text |
id | pubmed-9500788 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95007882022-09-24 Mesoporous Nanoparticles for Diagnosis and Treatment of Liver Cancer in the Era of Precise Medicine Wu, Han Wang, Ming-Da Zhu, Jia-Qi Li, Zhen-Li Wang, Wan-Yin Gu, Li-Hui Shen, Feng Yang, Tian Pharmaceutics Review Primary liver cancer is the seventh-most-common cancer worldwide and the fourth-leading cause of cancer mortality. In the current era of precision medicine, the diagnosis and management of liver cancer are full of challenges and prospects. Mesoporous nanoparticles are often designed as specific carriers of drugs and imaging agents because of their special morphology and physical and chemical properties. In recent years, the design of the elemental composition and morphology of mesoporous nanoparticles have greatly improved their drug-loading efficiency, biocompatibility and biodegradability. Especially in the field of primary liver cancer, mesoporous nanoparticles have been modified as highly tumor-specific imaging contrast agents and targeting therapeutic medicine. Various generations of complexes and structures have been determined for the complicated clinical management requirements. In this review, we summarize these advanced mesoporous designs in the different diagnostic and therapeutic fields of liver cancer and discuss the relevant advantages and disadvantages of transforming applications. By comparing the material properties, drug-delivery characteristics and application methods of different kinds of mesoporous materials in liver cancer, we try to help determine the most suitable drug carriers and information media for future clinical trials. We hope to improve the fabrication of biomedical mesoporous nanoparticles and provide direct evidence for specific cancer management. MDPI 2022-08-23 /pmc/articles/PMC9500788/ /pubmed/36145508 http://dx.doi.org/10.3390/pharmaceutics14091760 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Wu, Han Wang, Ming-Da Zhu, Jia-Qi Li, Zhen-Li Wang, Wan-Yin Gu, Li-Hui Shen, Feng Yang, Tian Mesoporous Nanoparticles for Diagnosis and Treatment of Liver Cancer in the Era of Precise Medicine |
title | Mesoporous Nanoparticles for Diagnosis and Treatment of Liver Cancer in the Era of Precise Medicine |
title_full | Mesoporous Nanoparticles for Diagnosis and Treatment of Liver Cancer in the Era of Precise Medicine |
title_fullStr | Mesoporous Nanoparticles for Diagnosis and Treatment of Liver Cancer in the Era of Precise Medicine |
title_full_unstemmed | Mesoporous Nanoparticles for Diagnosis and Treatment of Liver Cancer in the Era of Precise Medicine |
title_short | Mesoporous Nanoparticles for Diagnosis and Treatment of Liver Cancer in the Era of Precise Medicine |
title_sort | mesoporous nanoparticles for diagnosis and treatment of liver cancer in the era of precise medicine |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500788/ https://www.ncbi.nlm.nih.gov/pubmed/36145508 http://dx.doi.org/10.3390/pharmaceutics14091760 |
work_keys_str_mv | AT wuhan mesoporousnanoparticlesfordiagnosisandtreatmentoflivercancerintheeraofprecisemedicine AT wangmingda mesoporousnanoparticlesfordiagnosisandtreatmentoflivercancerintheeraofprecisemedicine AT zhujiaqi mesoporousnanoparticlesfordiagnosisandtreatmentoflivercancerintheeraofprecisemedicine AT lizhenli mesoporousnanoparticlesfordiagnosisandtreatmentoflivercancerintheeraofprecisemedicine AT wangwanyin mesoporousnanoparticlesfordiagnosisandtreatmentoflivercancerintheeraofprecisemedicine AT gulihui mesoporousnanoparticlesfordiagnosisandtreatmentoflivercancerintheeraofprecisemedicine AT shenfeng mesoporousnanoparticlesfordiagnosisandtreatmentoflivercancerintheeraofprecisemedicine AT yangtian mesoporousnanoparticlesfordiagnosisandtreatmentoflivercancerintheeraofprecisemedicine |